Last reviewed · How we verify
JOINTSTEM
JOINTSTEM is an autologous mesenchymal stem cell therapy that promotes cartilage regeneration and reduces inflammation in damaged joints.
JOINTSTEM is an autologous mesenchymal stem cell therapy that promotes cartilage regeneration and reduces inflammation in damaged joints. Used for Osteoarthritis of the knee.
At a glance
| Generic name | JOINTSTEM |
|---|---|
| Also known as | autologous adipose-derived mesenchymal stem cells, Autologous Adipose Tissue derived MSCs, Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml |
| Sponsor | R-Bio |
| Drug class | Autologous mesenchymal stem cell therapy |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
JOINTSTEM consists of bone marrow-derived mesenchymal stem cells that are expanded ex vivo and injected directly into the joint. These cells differentiate into chondrocytes and produce anti-inflammatory cytokines, promoting cartilage repair and reducing joint inflammation. The therapy aims to halt or reverse degenerative joint disease through tissue regeneration rather than symptom management alone.
Approved indications
- Osteoarthritis of the knee
Common side effects
- Injection site pain or swelling
- Transient joint effusion
- Infection at injection site
Key clinical trials
- A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis (PHASE2, PHASE3)
- Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial (PHASE3)
- A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis (PHASE3)
- Follow-up Study for Participants Jointstem Clinical Trial (PHASE2)
- Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy (NA)
- Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration (NA)
- A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis (PHASE2)
- Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JOINTSTEM CI brief — competitive landscape report
- JOINTSTEM updates RSS · CI watch RSS
- R-Bio portfolio CI